Shares of Merck & Co. Inc. slipped 4.81% to $87.87 Tuesday, on what proved to be an all-around favorable trading session for ...

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

The Mayo Clinic and Xact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

The Davenport Value & Income Fund (DVIPX) generated a -4.18% total return in the fourth quarter of 2024. Click here to read ...